Litigation
Novartis Pharmaceuticals Corp. v. Accord Healthcare, Inc. et al.
Reversed on rehearing; claims invalid21-1070
Auto-generating section 1 of 4: Case overview & background…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
Patents at issue (1)
Plaintiffs (1)
Defendants (2)
Summary
Appeal from D. Del. 1:18-cv-01043. The Federal Circuit first affirmed validity and infringement on January 3, 2022, then on rehearing vacated and reversed, holding the '405 patent claims invalid for lack of written description (38 F.4th 1013). Rehearing en banc was denied and mandate issued approximately October 18, 2022.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).